Abstract Purpose of Review Certain immunocompromised individuals are at risk for
protracted COVID-19, in which SARS-CoV-2 leads to a chronic viral infection. However, the …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is cause of the novel
coronavirus disease (COVID-19). In the last two years, SARS-CoV-2 has infected millions of …

Immunocompromised patients still experience unpredictable courses of COVID-19, despite
that effective vaccines and drugs against SARS-CoV-2 are now available. Antiviral …

Epithelial cells from mucociliary portions of the airways can be readily grown and expanded
in vitro. When grown on a porous membrane at an air–liquid interface (ALI) the cells form a …

Background Throughout the time of the global pandemic of SARS-CoV-2 virus, there has
been a compelling necessity for the development of effective antiviral agents and …

This document is intended as a guide for diagnosis and management of Coronavirus
Disease 2019 (COVID-19), caused by the virus SARS-CoV-2, in adult and pediatric HCT …

Remdesivir was the first antiviral drug to be approved for the treatment of severe COVID-19;
followed by molnupiravir (another prodrug of a nucleoside analogue) and the protease …

The COVID-19 pandemic ignited research centered around the identification of robust
biomarkers and therapeutic targets. SARS-CoV-2, the virus responsible, hijacks the …

Molnupiravir is an antiviral drug against viral RNA polymerase activity approved by the FDA
for the treatment of COVID-19, which is metabolized to β-D-N4-hydroxycytidine (NHC) in …

Main protease (Mpro) is a superior target for anti-SARS-COV-2 drugs. PF-07304814 is a
phosphate ester prodrug of PF-00835231 that is rapidly metabolized into the active …